Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VISKAZIDE

HYDROCHLOROTHIAZIDE; PINDOLOL

Standard Dose
25MG;5MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview VISKAZIDE is listed in Drugs@FDA under application 018872 (NDA).

Marketing status: Discontinued Active ingredient HYDROCHLOROTHIAZIDE; PINDOLOL Form and strength TABLET;ORAL - 25MG;5MG Sponsor NOVARTIS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview VISKAZIDE is listed in Drugs@FDA under application 018872 (NDA). Marketing status: Discontinued Active ingredient HYDROCHLOROTHIAZIDE; PINDOLOL Form and strength TABLET;ORAL - 25MG;5MG Sponsor NOVARTIS Submission history See approval history documents.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.